Pharmacokinetics Laboratory

About the PK Lab
  • The Center for Drug Design (CDD) Pharmacokinetics (PK) lab aims to facilitate medicinal chemists' efforts to discover new lead candidates with proper drug-like properties, and to obtain research funding and publish academic research findings.
  • The PK lab is supported by the CDD and was initially established to provide ADME/PK support within the center. In the last five years, the lab has studied the preclinical ADME/PK of more than 300 compounds from various CDD drug discovery projects, and has contributed to the application of two awarded R01 NIH grants and the publication of 16 joint manuscripts.
  • The PK lab is equipped with a state-of-the-art LC-MS instrument (Agilent 1260 HPLC and AB Sciex QTrap 5500 MS) that is used to detect and quantitate small molecules in biological matrices.
  • The PK lab also manages an Agilent 6230B Time of Flight LC/MS system with capability of high resolution mass.
  • The PK lab has licensed Phoenix WinNonlin software for PK data analysis and modeling.

LC/MS/MS bioanalytical services

  • Express LC/MS/MS method development
  • Advanced LC/MS/MS bioanalysis method development and validation according to FDA guidelines
  • Quantitative analysis of small molecules and peptides from biological samples (including plasma and other organs from in vivo bio-distribution studies), or food and environmental samples

In vitro ADME

  • Microsomal stability, Plasma stability, S9 stability, Aqueous stability
  • Cytochrome P450 inhibition, Cytochrome P450 reaction phenotyping
  • Plasma protein binding, Brain tissue binding, Blood to plasma ratio
  • Solubility
  • Caco-2, MDCK and PAMPA permeability

Rodent PK 

  • Oral bioavailability of drugs in mice and rats 
  • PK Data analysis with non-compartmental or compartmental models